This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Assertio Therapeutics looks to get out of Glumetza antitrust case

( December 23, 2019, 22:31 GMT | Official Statement) -- MLex Summary: Assertio Therapeutics others filed a motion to dismiss end-payor plaintiffs and direct purchaser plaintiffs’ claims alleging that it engaged in an illegal pay-for-delay agreement concerning the diabetes drug Glumetza, resulting in higher prices. They say that the relevant patent settlement is seven years old and Assertio has neither manufactured nor sold Glumetza for at least the last eight years.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections